ST Pharm's Shift to Deficit in H1: Will H2 Bring a Turnaround?
ST Pharm, which recorded a deficit in the first half of the year, is expected to see a rebound in performance in the…
카테고리 찾아보기
Bio-Pharm
Why Celltrion’s Retail Investors Oppose the Merger with Celltrion Pharm
“60,000 Celltrion shareholders firmly oppose the merger with Celltrion Pharm, which undermines shareholder value. We…
Will GC Biopharma's Immune Globulin 'Alyglo' Succeed in the U.S. Market?
GC Biopharma Corp's new immune globulin drug 'Alyglo' is set to enter the U.S. market after 8 years of efforts.…
Daewoong, Unveils 'One Product, One Trillion Won Revenue' Vision
Daewoong Pharmaceutical has unveiled its next growth strategy, the 'One Product, one Trillion Won Plan.' The goal is to…
Samsung Bioepis Secures FDA Approval for High-Cost Rare Disease Drug in the U.S.
Samsung Bioepis announced on the 23rd that it has received approval from the U.S. Food and Drug Administration (FDA) for…
Celltrion Finalizing Preparations for Third Plant's Commercial Production
Celltrion announced on the 23rd that its third plant, located in Songdo, Incheon, is undergoing final validation before…
Following the 'Galaxy Ring' Controversy, Samsung Faces Earphone Troubles
Samsung Electronics has decided to effectively recall its new product, 'Buds 3 Pro', following criticisms of…
GC WellBeing Anticipates Strong Market Penetration in China with Placental Injections…
GC WellBeing Corporation Expected to See Stock Price Rise in H2 with Stable Sales Growth in Chinese Market
Analysts…
"Global Clinical Trials Shift from Europe to US and China"
The focus of global clinical trials is shifting from Europe to the United States and China, according to a…
"SK Biopharm's Epilepsy Drug Excels in the U.S."... Growth Expected in the Second Half
SK Biopharm is expected to continue its performance growth in the second half of the year, driven by the stable sales…
DongA ST, Subsidiary MASH and Obesity Drug Clinical Results Expected This Year
Analysts in the securities industry suggest paying attention to the clinical results to be released later this year by…
Biosimilar Onslaught Dents Global Blockbuster Humira
The dominance of the autoimmune disease treatment Humira (active ingredient: adalimumab), once the world's best-selling…
D&D Pharmatech "Confident in MASH and Obesity Drug Efficacy…Targeting 100 Trillion…
“The GLP-1 obesity treatment market is expected to grow to 100 trillion won( approximately 77…
A New Treatment Option Emerges for Non-Hodgkin's Lymphoma
A new treatment option for managing refractory blood cancer, specifically Diffuse Large B-Cell Lymphoma…
Hanmi Pharmaceutical Group Declares End to Management Dispute
The management dispute within Hanmi Pharmaceutical Group that has heated up the pharmaceutical and biotech industry for…
Reasons to Watch HK Inno.N in the Second Half of the Year
HK Inno.N Corporation is emerging as a company to watch in the second half of the year, following strong performance and…
Celltrion Receives UK Approval for Asthma Drug Biosimilar 'Xolair'
Celltrion has announced that their biosimilar Omvoh (CT-P39), a treatment for allergic asthma and chronic idiopathic…
Song Young-sook to step down as chairwoman of Hanmi Pharm
Song Young-sook, chairwoman of Hanmi Pharm. Co., Ltd. has stepped down from the management of the company and said he…
Approval of Alzheimer's Drug ‘Donanemab’ Brings Positive Outlook for Duchembio
The FDA approval of Eli Lilly's 'Donanemab' (marketed as Kisunla), the third Alzheimer's treatment globally, is…
ABL Bio Confident in Technology Transfer This Year, Secures $310 million for Development
ABL Bio has announced its ambition to become a global leader in the targeted cancer therapy market through the…